Last reviewed · How we verify
NCT03466697
Role of Dopamine Transporter in Glucose Control
NA trial testing Glucose injection/Normal saline injection in Obesity in 40 participants. Completed in 20 December 2021.
20 December 2021
Quick facts
| Lead sponsor | Pusan National University Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 40 |
| Start date | 14 March 2018 |
| Primary completion | 20 December 2021 |
| Estimated completion | 20 December 2021 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Glucose injection/Normal saline injection
Conditions studied
- Obesity — all drugs for Obesity →
Sponsor
Pusan National University Hospital
Who can join
Adults 20 to 40, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Healthy subjects will be enrolled in this study. Each subject will be scanned twice with F18-FP-CIT PET which is commercially available. F18-FP-CIT reflects dopamine transporter availability of striatum. Before each PET scan, subject will be injected either glucose or normal saline. Therefore, PET scan will reflect the changes of dopamine transporter availability after the injection of glucose.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03466697
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Pusan National University Hospital trials
Trials by the same sponsor.
- NCT07073365 — Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor The · Phase 2 · recruiting
- NCT06878495 — Efficacy and Safety of Discontinuing 5-ASA in Patients With Inflammatory Bowel Disease · NA · not yet recruiting
- NCT06805123 — Early Feeding Versus Delayed Feeding After Colorectal Endoscopic Submucosal Dissection · NA · recruiting
- NCT06752395 — Cryobiopsy Vs. Forceps Biopsy for Peripheral Pulmonary Lesions · NA · enrolling by invitation
- NCT07455552 — Comparison of Telemedicine-based and Home-based Inspiratory Muscle Training After Lung Resection in High-risk Patients · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03466697 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pusan National University Hospital
- Last refreshed: 20 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03466697.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing